Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q2 2026 FINANCIAL RESULTS Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized M

Dianthus Therapeutics (Nasdaq: DNTH) said it initiated the Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis (AChR+). The global, randomized, placebo-controlled study enrolls ~195 patients; claseprubart 300mg/2mL is dosed Q2W or Q4W vs placebo. Top-line results are expected in 2H’28.

Dollar General (DG) and Dollar Tree (DLTR) reported strong quarterly results, beating sales expectations. Both raised full-year profit forecasts, aided by tariff refunds. DG increased its same-store sales growth forecast and announced a $700M share repurchase plan. Analysts raised price targets for both. Concerns remain about the temporary nature of tariff refund benefits and rising costs.

Wells Fargo upgraded BWX Technologies (BWXT) to Equal Weight, lowering its target price to $170. The company reported Q2 2026 revenue of $901.6M, up from $764M last year, with adjusted EPS of $1.07. BWXT raised its full-year revenue guidance to $3.8B and adjusted EPS guidance to $4.70-$4.80. The stock is down 11.89% year-to-date. Management highlighted growth in commercial operations, while analysts noted risks related to revenue mix and leverage.

Hafnia Limited (NYSE:HAFN) reported a record Q2 net profit of $277.8M, driven by elevated freight rates due to geopolitical disruptions. The company's TCE income reached $372.9M, with a 44.6% annualized ROE. Hafnia declared a $250M dividend, reflecting a 21% annualized yield. Management cautioned that earnings may not be sustainable if disruptions ease, with Q3 revenue coverage at lower rates.

APi Group (APG) reported Q2 2026 revenue of $2.3B, up 13.3% YoY, and raised full-year guidance. Analysts see 31% upside to $52.40. BrightSpring Health (BTSG) saw Q2 revenue rise 23% to $3.9B, lifted guidance, and has a 30% upside to $78.25.